Levonorgestrel-releasing intrauterine system in contraception

References

• Kottke M, Cwiak C. Nondaily contraceptive options user benefits, potential for high continuation and counselling issues. Obstet. Gynecol. Surv.63(10), 661–668 (2008).
   PubMedGoogle Scholar
• Backman T, Huhtala S, Luoto R et al. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet. Gynecol.99, 608–613 (2002).
   PubMed Web of Science ®Google Scholar
• Oddens BJ. Women’s satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning and sterilization among 1466 women. Contraception59, 277–286 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol.179, 577–582 (1998).
   PubMed Web of Science ®Google Scholar
• Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst. Rev.19(4), CD002126 (2005).
   Google Scholar
• Bahamondes L, Petta Ca, Fernandes A, Monteiro I. Use of levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception75(Suppl. 6), S134–S139 (2007).
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum. Reprod.20(3), 789–793 (2005).
   PubMed Web of Science ®Google Scholar
• Prager S, Darney PD. The levonorgestrel intrauterine system in nulliparous women. Contraception75(Suppl. 6), S12–S15 (2007).
   PubMed Web of Science ®Google Scholar
• Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performancy of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception69, 407–412 (2004).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion with 5 years’ follow-up. Contraception68(1), 31–34 (2003).
   PubMed Web of Science ®Google Scholar
• Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst. Rev.18(4), CD1777 (2004).
   Google Scholar
• Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380Ag intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception75(5), 346–351 (2005).
   Google Scholar
• Mirena®, package insert. Schering Health Care Ltd, Berlin, Germany.
   Google Scholar
• Silverberg SG, Haukkamaa M, Arko H et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int. J. Gynecol. Pathol.5, 235–241 (1986).
   PubMed Web of Science ®Google Scholar
• Jonsson B, Landgren B-M, Eneroth P. Effect of various IUDs on the composition of cervical mucus. Contraception43, 447–458 (1991).
   PubMed Web of Science ®Google Scholar
• Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel-contraception 75(Suppl. 6), S93–S98 (2007).
   Google Scholar
• Pekonen F, Nyman T, Lahteenmaki P et al. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-I production in the human endometrium. J. Clin. Endocrinol. Metab.75, 660–664 (1992).
   PubMed Web of Science ®Google Scholar
• Rutanen EM, Salmi A, Nyman T. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGR.II and IGF-binding protein-I are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol. Hum. Reprod.3, 749–754 (1997).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Lahteeenmaki P, Rutanen EM. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-I. Acta Obstet. Gynecol. Scand.78, 423–428 (1999).
   PubMed Web of Science ®Google Scholar
• Barbosa I, Bakos O, Olsson S-E et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception42, 51–66 (1990).
   PubMed Web of Science ®Google Scholar
• Nilsson Cg, Lahteenmaki P, Luukkainen T. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device. Contraception21, 155–164 (1980).
   PubMed Web of Science ®Google Scholar
• Andersson K, Odlind V, Rybo F. Levonorgestrel-releasing and copper-releasing (NovaT) IUDs during five years of use: a randomised comparative trial. Contraception49, 56–72 (1994).
   PubMed Web of Science ®Google Scholar
• Sivin I, El Mahgoub S, McCarthy T et al. Long-term contraception with the levonorgestrel 20 µg/day (Lng20) and the copper T 380Ag intrauterine devices: a five-year randomised study. Contraception42, 361–378 (1990).
   PubMed Web of Science ®Google Scholar
• Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J. Fam. Plann. Reprod. Health Care28(2), 73–77 (2002).
   PubMed Web of Science ®Google Scholar
• Backman T, Huhtala S, Rauramo I et al. Pregnancies during the user of the levonorgestrel-releasing intrauterine system. Am. J. Obstet. Gynecol.191, 50–54 (2004).
   Google Scholar
• Franks AL, Beral V, Cates W et al. Contraception and ectopic pregnancy risk. Am. J. Obstet. Gynecol.163, 1120–1123 (1990).
   PubMed Web of Science ®Google Scholar
• Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet. Gynecol.78, 291–298 (1991).
   PubMed Web of Science ®Google Scholar
• Trivendi A, Ngu A. Failed cervical pregnancy with levonorgestrel containing intrauterine contraceptive device. Aust. NZ. J. Obstet. Gynaecol.42, 201–211 (2002).
   Google Scholar
• Masters R, Miskry T, Lowe D, Burton R, Shah S, Guillbaud J. Report of ectopic pregnancies associated with the levonorgestrel intrauterine system. Br. J. Fam. Plann.23, 25–26 (1997).
   Google Scholar
• Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception54, 201–208 (1996).
   PubMed Web of Science ®Google Scholar
• Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids65, 699–702 (2000).
   PubMed Web of Science ®Google Scholar
• Jia MX, Zhou LY, Ren S, Dong L, Xiao B. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv. Contraception8, 33–40 (1992).
   PubMedGoogle Scholar
• Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception129–132 (2002).
   PubMedGoogle Scholar
• Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception67, 87–01 (2003).
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M, Zhou I, Coulter D. Insertion of intrauterine devices; a comparison of experience with Mirena and Multiload 375 during post-marketing monitoring in New Zealand. NZ. Med. J.116, 1–7 (2003).
   Google Scholar
• Jenssen JT, Nelson AL, Costales AC. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception77(1), 22–29 (2008).
   PubMedGoogle Scholar
• Cox M, Blacksell S. Clinical performance of the levonorgestrel intra-uterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 12-month report. Br. J. Fam. Plann.26(3), 143–147 (2000).
   PubMedGoogle Scholar
• Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. Acta Obstet. Gynecol. Scand.78, 716–721 (1999).
   PubMed Web of Science ®Google Scholar
• Veldhuis HM, Vos AG, Lagro-Janssen AL. Complications of the intrauterine device in nulliparous and parous women. Eur. J. Gen. Pract.10, 82–87 (2004).
   PubMedGoogle Scholar
• Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three year’s comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet. Gynecol.77, 261–264 (1991).
   PubMed Web of Science ®Google Scholar
• Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, Duselman GA. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception73(3), 257–260 (2006).
   PubMed Web of Science ®Google Scholar
• Kayikcioglu F, Gunes M, Ozdegirmenci O, Haberal A. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study. Contraception73(5), 528–531 (2006).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Martikainen H, McCarthy MI et al. Comparison of metabolic and inflammatory outcome in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am. J. Obstet. Gynecol.199(5), 529.e1–529.e10 (2008)
   Google Scholar
• Backman T, Rauramo I, Jaakkola K et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet. Gynecol.106, 813–817 (2005).
   PubMed Web of Science ®Google Scholar
• Brache V, Faundes A, Alvarez F et al. Nonmenstrual adverse events during user of implantable contraceptive for women; data from clinical trials. Contraception65, 63–74 (2002).
   PubMed Web of Science ®Google Scholar
• Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG107(3), 335–339 (2000).
   PubMed Web of Science ®Google Scholar
• Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet. Gynecol.9, 608–613 (2002).
   Google Scholar
• Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorestrel-releasing intrauterine system (LNG IUS) in HIV-infected women – effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum. Reprod.21, 2857–2861 (2006).
   PubMed Web of Science ®Google Scholar
• Narayanan TJ, Chowdary GV, Murthy JM. Contraceptive-related cerebral venous thrombosis with profuse vaginal bleed. Neurocrit. Care2, 292–295 (2005).
   PubMedGoogle Scholar